Gene therapy restores vision in a canine model of childhood blindness
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The relationship between the neurosensory photoreceptors and the adjacent retinal pigment epithelium (RPE) controls not only normal retinal function, but also the pathogenesis of hereditary retinal degenerations. The molecular bases for both primary photoreceptor and RPE diseases that cause blindness have been identified. Gene therapy has been used successfully to slow degeneration in rodent models of primary photoreceptor diseases, but efficacy of gene therapy directed at photoreceptors and RPE in a large-animal model of human disease has not been reported. Here we study one of the most clinically severe retinal degenerations, Leber congenital amaurosis (LCA). LCA causes near total blindness in infancy and can result from mutations in RPE65 (LCA, type II; MIM 180069 and 204100). A naturally occurring animal model, the RPE65-/- dog, suffers from early and severe visual impairment similar to that seen in human LCA. We used a recombinant adeno-associated virus (AAV) carrying wild-type RPE65 (AAV-RPE65) to test the efficacy of gene therapy in this model. Our results indicate that visual function was restored in this large animal model of childhood blindness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [64]
Citations
Cites
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Identification of the gene responsible for Best macular dystrophy
Petrukhin, K., Koisti, M. J., Bakall, B., Li, W., Xie, G., Marknell, T., Sandgren, O., Forsman, K., Holmgren, G., Andreasson, S., et al. (1998) · Nature Genetics · doi:10.1038/915 · Cited by 689
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
Mutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407
Self-citationBiochemistry of visual pigment regeneration: the Friedenwald lecture.
Saari, J. C. (2000) · PubMed · Cited by 270
Simon, A., Hellman, U., Wernstedt, C., & Eriksson, U. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1107 · Cited by 254
Van Hooser, J. P., Aleman, T. S., He, Y.-G., Cideciyan, A. V., Kuksa, V., Pittler, S. J., Stone, E. M., Jacobson, S. G., & Palczewski, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150236297 · Cited by 252
Self-citationAguirre, G. K., Baldwin, V. J., Pearce‐Kelling, S., Narfström, K. L., Ray, K., & Acland, G. M. (1998) · PubMed · Cited by 244
Self-citationBennett, J., Maguire, A. M., Cideciyan, A. V., Schnell, M., Glover, E., Anand, V., Aleman, T. S., Chirmule, N., Gupta, A. R., Huang, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9920 · Cited by 242
Self-citation
Cited by
Items 201–300 of 1,000
Retinoids and Retinal Diseases
Kiser, P. D., & Palczewski, K. (2016) · Annual Review of Vision Science · doi:10.1146/annurev-vision-111815-114407 · Cited by 108
“…protein CRALBP: cellular retinaldehyde-binding protein investigation: RPE65 gene therapy to restore a functional RPE-based retinoid cycle (Acland et al. 2001, Bainbridge et al. 2008, Maguire et al. 2008) and treatment with an artificial chromophore (9-cis-RAL) to bypass the metabolic…”
Structure and function of ABCA4 and its role in the visual cycle and Stargardt macular degeneration
Molday, R. S., Garces, F. A., Scortecci, J. F., & Molday, L. L. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101036 · Cited by 107
Beltran, W. A., Boye, S. L., Boye, S. E., Chiodo, V. A., Lewin, A. S., Hauswirth, W. W., & Aguirre, G. D. (2010) · Gene Therapy · doi:10.1038/gt.2010.56 · Cited by 96
Self-citationA look into retinal organoids: methods, analytical techniques, and applications
Afanasyeva, T. A. V., Corral-Serrano, J. C., Garanto, A., Roepman, R., Cheetham, M. E., & Collin, R. W. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03917-4 · Cited by 117
Identification of the RPE65 protein in mammalian cone photoreceptors.
Znoiko, S. L., Crouch, R. K., Moiseyev, G. P., & Xing, J. (2002) · PubMed · Cited by 120
Nanoparticle applications in ocular gene therapy
Cai, X., Conley, S. M., & Naash, M. I. (2007) · Vision Research · doi:10.1016/j.visres.2007.07.012 · Cited by 111
Wiley, L. A., Burnight, E. R., Songstad, A. E., Drack, A. V., Mullins, R. F., Stone, E. M., & Tucker, B. A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.10.002 · Cited by 124
“Efficacy of RPE65 gene replacement was demonstrated in a canine model in 2001 (Acland et al., 2001), and over thirteen years later, fewer than 100 patients have been treated world-wide and the Phase III clinical trial is still ongoing.”
BackgroundClark, A. F., & Yorio, T. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1106 · Cited by 114
Thompson, D. A., Janecke, A. R., Lange, J., Feathers, K. L., Hübner, C. A., McHenry, C. L., Stockton, D. W., Rammesmayer, G., Lupski, J. R., Antinolo, G., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi411 · Cited by 105
Self-citationMellersh, C. S., Boursnell, M. E. G., Pettitt, L., Ryder, E. J., Holmes, N. G., Grafham, D. V., Forman, O. P., Sampson, J., Barnett, K. C., Blanton, S. H., et al. (2006) · Genomics · doi:10.1016/j.ygeno.2006.05.004 · Cited by 115
Mutation in CEP290 Discovered for Cat Model of Human Retinal Degeneration
Menotti-Raymond, M., David, V. A., Schaffer, A. A., Stephens, R., Wells, D., Kumar-Singh, R., O'Brien, S. J., & Narfstrom, K. (2007) · Journal of Heredity · doi:10.1093/jhered/esm019 · Cited by 104
Koenekoop, R. K., Sui, R., Sallum, J., van den Born, L. I., Ajlan, R., Khan, A., den Hollander, A. I., Cremers, F. P. M., Mendola, J. D., Bittner, A. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60153-7 · Cited by 103
AAV-mediated photoreceptor transduction of the pig cone-enriched retina
Mussolino, C., della Corte, M., Rossi, S., Viola, F., Di Vicino, U., Marrocco, E., Neglia, S., Doria, M., Testa, F., Giovannoni, R., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.3 · Cited by 102
Jo, D. H., Song, D. W., Cho, C. S., Kim, U. G., Lee, K. J., Lee, K., Park, S. W., Kim, D., Kim, J. H., Kim, J.-S., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax1210 · Cited by 102
Retinal remodeling in the Tg P347L rabbit, a large‐eye model of retinal degeneration
Jones, B. W., Kondo, M., Terasaki, H., Watt, C. B., Rapp, K. D., Anderson, J., Lin, Y., Shaw, M. V., Yang, J., & Marc, R. E. (2011) · The Journal of Comparative Neurology · doi:10.1002/cne.22703 · Cited by 109
Adeno-Associated Virus-Vectored Gene Therapy for Retinal Disease
Dinculescu, A., Glushakova, L., Min, S.-H., & Hauswirth, W. W. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.649 · Cited by 100
Self-citationSubretinal injection techniques for retinal disease: A review
Irigoyen, C., Amenabar Alonso, A., Sanchez-Molina, J., Rodríguez-Hidalgo, M., Lara-López, A., & Ruiz-Ederra, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164717 · Cited by 106
“The vector was injected using a 30G anterior chamber cannula through a pars plana approach [35].”
MethodIntravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery
Hartman, R. R., & Kompella, U. B. (2018) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0121 · Cited by 100
Photoreceptor Layer Topography in Children with Leber Congenital Amaurosis Caused by RPE65 Mutations
Jacobson, S. G., Cideciyan, A. V., Aleman, T. S., Sumaroka, A., Windsor, E. A. M., Schwartz, S. B., Heon, E., & Stone, E. M. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2121 · Cited by 101
“Another theoretical contributor to retinal degeneration is RPE disease with secondary photoreceptor loss, such as could occur from continuous retinyl ester accumulation.(9,25,27,38,39) It has been argued, however, that this does not have a significant role in the loss of rod cells.”
BackgroundSelf-citationAleman, T. S., Jacobson, S. G., Chico, J. D., Scott, M. L., Cheung, A. Y., Windsor, E. A. M., Furushima, M., Redmond, T. M., Bennett, J., Palczewski, K., et al. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-1230 · Cited by 101
Self-citationGene therapy for visual loss: Opportunities and concerns
Lee, J. H., Wang, J.-H., Chen, J., Li, F., Edwards, T. L., Hewitt, A. W., & Liu, G.-S. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.08.003 · Cited by 100
“Subsequently, in 2001, a preclinical study using a canine model of LCA2 (naturally occurring Rpe65−/−) showed a marked improvement in visual function using AAV-mediated gene therapy (Acland et al., 2001).”
Retinitis pigmentosa: understanding the clinical presentation, mechanisms and treatment options
Kalloniatis, M., & Fletcher, E. L. (2004) · Clinical and Experimental Optometry · doi:10.1111/j.1444-0938.2004.tb03152.x · Cited by 118
Chiu, W., Lin, T.-Y., Chang, Y.-C., Lai, H. I. A. M., Lin, S.-C., Ma, C., Yarmishyn, A. A., Lin, S.-C., Chang, K.-J., Chou, Y.-B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094534 · Cited by 116
“The dog model of RPE65-mutated LCA was established in 1998 [46], and was used for preclinical studies in 2001 [47].”
MethodRetinitis pigmentosa: Genes, Proteins and Prospects
Hims, M. M., Daiger, S. P., & Inglehearn, C. F. (2003) · Developments in Ophthalmology · doi:10.1159/000072042 · Cited by 99
Samardzija, M., von Lintig, J., Tanimoto, N., Oberhauser, V., Thiersch, M., Reme, C. E., Seeliger, M., Grimm, C., & Wenzel, A. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm304 · Cited by 98
“experiments to restore rod and cone photoreceptor function (rd12, (14); Rpe65, (15-18); dog, (19-22)).”
On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosa
Aherne, A., Kennan, A., Kenna, P. F., McNally, N., Lloyd, D. G., Alberts, I. L., Kiang, A., Humphries, M. M., Ayuso, C., Engel, P. C., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh061 · Cited by 105
“Notwithstanding recent successes in restoration of visual function or preservation of the retina in autosomal recessive forms of degenerative retinopathy, including the Briard dog model of Leber congential amaurosis ( 36 ) and the RCS rat following AAV-mediated delivery of therapeutic genes to retinal tissues (37), th…”
BackgroundMiyadera, K., Acland, G. M., & Aguirre, G. D. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9361-3 · Cited by 113
“Cones alone are affected in cdAMAL and cdGSPT because of a mutation in CNGB3, a cone–specific gene, whereas both rods and cones are dysfunctional in cLCA because a mutation in RPE65, a RPE-specific isomerohydrolase, impairs the retinoid cycle and 11-cis-retinal is not made (Fig.”
InfluentialSelf-citationPark, K., Chen, Y., Hu, Y., Mayo, A. S., Kompella, U. B., Longeras, R., & Ma, J.-X. (2009) · Diabetes · doi:10.2337/db08-1327 · Cited by 97
“Currently, viral vectors are the most commonly used means for gene delivery because of their high efficiencies (16,17).”
BackgroundGene Therapy for the Nervous System: Challenges and New Strategies
Maguire, C. A., Ramirez, S. H., Merkel, S. F., Sena‐Esteves, M., & Breakefield, X. O. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0299-5 · Cited by 110
“Of all the targets for gene therapy in the CNS, the eye is likely the most “immune privileged” and accessible, and excellent transgene stability and therapeutic efficacy has been reported here in preclinical models [39, 40] and clinical trials [41, 42].”
BackgroundSunshine, J. C., Sunshine, S. B., Bhutto, I., Handa, J. T., & Green, J. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037543 · Cited by 95
Buch, P. K., MacLaren, R. E., Durán, Y., Balaggan, K. S., MacNeil, A., Schlichtenbrede, F. C., Smith, A. J., & Ali, R. R. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.019 · Cited by 96
Jacobs, J. B., & Dell’Osso, L. F. (2004) · Journal of Vision · doi:10.1167/4.7.7 · Cited by 99
Lai, C., Yu, M. J. T., Brankov, M., Barnett, N. L., Zhou, X., Redmond, T. M., Narfström, K. L., & Rakoczy, P. E. (2004) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-2-3 · Cited by 100
Retinal pigment epithelium 65 kDa protein (RPE65): An update
Kiser, P. D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101013 · Cited by 91
Gene therapy of inherited diseases
Fischer, A., & Cavazzana, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60874-0 · Cited by 117
Retinal dystrophies, genomic applications in diagnosis and prospects for therapy.
Nash, B. M., Wright, D. C., Grigg, J., Bennetts, B., & Jamieson, R. V. (2015) · PubMed · doi:10.3978/j.issn.2224-4336.2015.04.03 · Cited by 94
Golczak, M., Maeda, A., Bereta, G., Maeda, T., Kiser, P. D., Hunzelmann, S., von Lintig, J., Blaner, W. S., & Palczewski, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708982200 · Cited by 93
Lipid Nanoparticles for Ocular Gene Delivery
Wang, Y., Rajala, A., & Rajala, R. (2015) · Journal of Functional Biomaterials · doi:10.3390/jfb6020379 · Cited by 93
Recombinant AAV-mediated gene transfer to the retina: gene therapy perspectives
Rolling, F. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302366 · Cited by 100
Generation of a Transgenic Rabbit Model of Retinal Degeneration
Kondo, M., Sakai, T., Komeima, K., Kurimoto, Y., Ueno, S., Nishizawa, Y., Usukura, J., Fujikado, T., Tano, Y., & Terasaki, H. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2863 · Cited by 102
Rescue of Photoreceptor Degeneration by Curcumin in Transgenic Rats with P23H Rhodopsin Mutation
Vasireddy, V., Chavali, V. R. M., Joseph, V. T., Kadam, R. S., Lin, J. H., Jamison, J. A., Kompella, U. B., Reddy, G. B., & Ayyagari, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021193 · Cited by 99
“Gene replacement therapy by delivering missing genes to the retina by way of injection has been shown to be effective in treating a recessive retinal degeneration lebers congenital amaurosis due to mutations in the RPE65 gene [50,51].”
BackgroundSagdullaev, B. T., Aramant, R. B., Seiler, M. J., Woch, G., & McCall, M. A. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-0615 · Cited by 92
“One focus is on the development of gene therapies, such as the use of antisense oligonucleotides or ribozymes.(7,13,14) These specific gene therapies, although promising, are limited to a particular gene defect and thus probably will be developed for only the most common forms of RP.”
BackgroundBuie, L. K., Rasmussen, C. A., Porterfield, E. C., Ramgolam, V. S., Choi, V. W., Markovic-Plese, S., Samulski, R. J., Kaufman, P. L., & Borrás, T. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-3847 · Cited by 92
Yzer, S., Leroy, B. P., De Baere, E., de Ravel, T. J., Zonneveld, M. N., Voesenek, K., Kellner, U., Ciriano, J. P. M., de Faber, J.-T. H. N., Rohrschneider, K., et al. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0848 · Cited by 92
Paunescu, K., Wabbels, B., Preising, M. N., & Lorenz, B. (2004) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-004-1020-x · Cited by 94
“naturally occurring blindness [1, 26, 27, 36].”
De, S., & Sakmar, T. P. (2002) · The Journal of General Physiology · doi:10.1085/jgp.20028566 · Cited by 90
“Moreover, gene transfer to ocular cells is presently a promising approach in the treatment of a variety of retinal disorders (Ali et al., 2000; Acland et al., 2001; Dejneka and Bennett, 2001).”
BackgroundIdentification of mouse AAV capsid-specific CD8+ T cell epitopes
Sabatino, D. E., Mingozzi, F., Hui, D. J., Chen, H., Colosi, P., Ertl, H. C. J., & High, K. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.009 · Cited by 91
A Single-Step Affinity Column for Purification of Serotype-5 Based Adeno-associated Viral Vectors
Auricchio, A., O'Connor, E., Hildinger, M., & Wilson, J. M. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0462 · Cited by 91
Beltran, W. A., Cideciyan, A. V., Iwabe, S., Swider, M., Kosyk, M. S., McDaid, K., Martynyuk, I., Ying, G.-S., Shaffer, J., Deng, W.-T., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509914112 · Cited by 89
“Over the last decades, preclinical evidence supporting the initiation of clinical trials of corrective gene therapy for RP has been based on successful proof of concept studies in which therapies were delivered before degeneration (11) or in models without a degenerative”
BackgroundSelf-citationRetinal Oxygenation and Oxygen Metabolism in Abyssinian Cats with a Hereditary Retinal Degeneration
Padnick‐Silver, L., Kang‐Mieler, J. J., Giuliano, E. A., Narfstro¨m, K., & Linsenmeier, R. A. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-1284 · Cited by 98
φC31 Integrase Confers Genomic Integration and Long-Term Transgene Expression in Rat Retina
Chalberg, T. W., Genise, H. L., Vollrath, D., & Calos, M. P. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-1252 · Cited by 90
Pharmacological Regulation of Protein Expression from Adeno-Associated Viral Vectors in the Eye
Auricchio, A., Rivera, V. M., Clackson, T., O'Connor, E. E., Maguire, A. M., Tolentino, M. J., Bennett, J., & Wilson, J. M. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0660 · Cited by 91
Self-citationGene therapy for inherited retinal and optic nerve degenerations
Moore, N. A., Morral, N., Ciulla, T. A., & Bracha, P. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389886 · Cited by 89
“naturally occurring animal model with mutated RPE65 [26,27].”
BackgroundBoth Ends of the Leash — The Human Links to Good Dogs with Bad Genes
Ostrander, E. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1204453 · Cited by 101
A Comprehensive Clinical and Biochemical Functional Study of a Novel RPE65 Hypomorphic Mutation
Lorenz, B., Poliakov, E., Schambeck, M., Friedburg, C., Preising, M. N., & Redmond, T. M. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1671 · Cited by 89
“The utility of gene therapy was established by preclinical trials in these dogs.(16) These are all null mutations and represent one end of a spectrum of disease.”
Williams, M. L., Coleman, J. E., Haire, S. E., Aleman, T. S., Cideciyan, A. V., Sokal, I., Palczewski, K., Jacobson, S. G., & Semple-Rowland, S. L. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030201 · Cited by 88
“The notion that therapies producing large contiguous regions of treated cells aid survival of the treated cells gains support from the success of subretinal delivery of viral vectors in studies of mouse [21,24] and dog [20,58] models of LCA2, a disease caused by mutations in the gene encoding RPE65.”
BackgroundSelf-citationStieger, K., Schroeder, J., Provost, N., Mendes-Madeira, A., Belbellaa, B., Meur, G. L., Weber, M., Deschamps, J.-Y., Lorenz, B., Moullier, P., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.283 · Cited by 88
Provost, N., Le Meur, G., Weber, M., Mendes-Madeira, A., Podevin, G., Cherel, Y., Colle, M.-A., Deschamps, J.-Y., Moullier, P., & Rolling, F. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.09.022 · Cited by 87
Robson, A. G., Egan, C. A., Luong, V. A., Bird, A. C., Holder, G. E., & Fitzke, F. W. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0211 · Cited by 87
“This is in keeping with the type 1 or “diffuse” form of RP,39 typically associated with sensitivity loss in the presence of high levels of rhodopsin.40 One implication is that intact photoreceptors may in future be amenable to functional rescue, as shown in recent animal models of RPE65.”
BackgroundLarge Animal Models of Inherited Retinal Degenerations: A Review
Winkler, P. A., Occelli, L. M., & Petersen‐Jones, S. M. (2020) · Cells · doi:10.3390/cells9040882 · Cited by 95
“The first proof-of-concept gene augmentation therapy that eventually led to the FDA approval of the first gene therapy product, Luxturna, for the treatment of LCA due to RPE65 mutations, was performed in a dog model [16].”
BackgroundKlein, M., & Birch, D. G. (2009) · Documenta Ophthalmologica · doi:10.1007/s10633-009-9204-7 · Cited by 85
Sheffield, V. C., & Stone, E. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1012354 · Cited by 92
Santos‐Ferreira, T., Völkner, M., Borsch, O., Haas, J., Cimalla, P., Vasudevan, P., Carmeliet, P., Corbeil, D., Michalakis, S., Koch, E., et al. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19087 · Cited by 91
McHenry, C. L. (2004) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-0909 · Cited by 84
“The latter approach is on the fast track with another RPE disease caused by mutations in the RPE65 gene,(46) based on preliminary successes in the naturally occurring mutant dog that show partial recovery of vision after subretinal injection of Rpe65-encoding, adeno-associated viral vector constructs.(47,48) There is…”
BackgroundSubretinal Gene Therapy of Mice With Bardet-Biedl Syndrome Type 1
Seo, S., Mullins, R. F., Dumitrescu, A. V., Bhattarai, S., Gratie, D., Wang, K., Stone, E. M., Sheffield, V., & Drack, A. V. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-11673 · Cited by 83
LaVail, M. M., Nishikawa, S., Steinberg, R. H., Naash, M. I., Duncan, J. L., Trautmann, N., Matthes, M. T., Yasumura, D., Lau-Villacorta, C., Chen, J., et al. (2017) · Experimental Eye Research · doi:10.1016/j.exer.2017.10.023 · Cited by 93
“, 2012), 2) gene-based therapy of recessively and dominantly inherited RDs, as well as viral vector delivery vehicles (Acland et al., 2001; Bennett et al., 1996; Dalkara et al., 2016; Dalkara and Sahel, 2014; Farrar et al., 2012; Laemmli, 1970; Lau et al., 2000; Lewin et al., 1998; Thompson et al., 2015; Trapani et al…”
Maeda, T., Cideciyan, A. V., Maeda, A., Golczak, M., Aleman, T. S., Jacobson, S. G., & Palczewski, K. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp163 · Cited by 83
“Proof-of-concept studies have been performed in small and large animal models of human genetic diseases resulting in retinoid cycle blockade and the results indicate increases in retinal-visual function (12,15,16,43).”
BackgroundSelf-citationProgress in retinal sheet transplantation
Aramant, R. B., & Seiler, M. J. (2004) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2004.05.003 · Cited by 91
“(2) Gene and pharmacologic therapy are being developed (Acland et al., 2001; Narfstrom et al., 2003), but they are still not in use in clinical trials at this time, although a clinical trial of gene therapy in Leber’s Congenital Amaurosis will probably be initiated soon (Dejneka et al.”
BackgroundGenetic characterization and disease mechanism of retinitis pigmentosa; current scenario
Ali, M. U., Rahman, M. S. U., Cao, J., & Yuan, P. (2017) · 3 Biotech · doi:10.1007/s13205-017-0878-3 · Cited by 96
“2 Recessive leber congenital amaurosis Acland et al. (2001), Lotery et al. (2000) SAG Phototransduction 2q37.”
BackgroundKomáromy, A. M., Rowlan, J. S., Corr, A. T. P., Reinstein, S. L., Boye, S. L., Cooper, A. E., Gonzalez, A., Levy, B., Wen, R., Hauswirth, W. W., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.50 · Cited by 82
Self-citationProspects for retinal gene replacement therapy
Smith, A. J., Bainbridge, J. W., & Ali, R. R. (2009) · Trends in Genetics · doi:10.1016/j.tig.2009.02.003 · Cited by 99
Kachi, S., Oshima, Y., Esumi, N., Kachi, M., Rogers, B. S., Zack, D. J., & Campochiaro, P. A. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302475 · Cited by 80
Lukason, M., DuFresne, E., Rubin, H., Pechan, P., Li, Q., Kim, I., Kiss, S., Flaxel, C., Collins, M., Miller, J., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.230 · Cited by 81
Self-citationRPE65 Gene Delivery Restores Isomerohydrolase Activity and Prevents Early Cone Loss in Rpe65−/−Mice
Chen, Y., Moiseyev, G., Takahashi, Y., & Ma, J.-X. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0965 · Cited by 80
“Several previous studies have shown that RPE65 gene delivery restores photopic and scotopic ERG in dogs with RPE65 mutations.(15,30) Similar effects were observed in Rpe65 / mice.”
BackgroundSasahara, M., Otani, A., Oishi, A., Kojima, H., Yodoi, Y., Kameda, T., Nakamura, H., & Yoshimura, N. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.080024 · Cited by 86
“Recent advances in gene therapy have led to successful reversal of retinal degeneration, slow (rds)(3) and retinal degeneration (rd)(4) phenotypes in mice, and the RPE65 phenotype in dogs.(5) The development of other neuroprotective approaches that affect secondary biochemical pathways would be advantageous because th…”
Docosahexaenoic acid attenuates microglial activation and delays early retinal degeneration
Ebert, S., Weigelt, K., Walczak, Y., Drobnik, W., Mauerer, R., Hume, D. A., Weber, B. H. F., & Langmann, T. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06286.x · Cited by 81
RDH12 and RPE65, Visual Cycle Genes Causing Leber Congenital Amaurosis, Differ in Disease Expression
Jacobson, S. G., Cideciyan, A. V., Aleman, T. S., Sumaroka, A., Schwartz, S. B., Windsor, E. A. M., Roman, A. J., Heon, E., Stone, E. M., & Thompson, D. A. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0599 · Cited by 81
Self-citationNon-viral strategies for ocular gene delivery
Oliveira, A. V., Rosa da Costa, A. M., & Silva, G. A. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.04.068 · Cited by 80
“[23] Currently, there are at least 7 active clinical trials using AAV-RPE65 for the development of treatment of RPE65-associated retinal diseases.”
BackgroundAdvances in gene therapy for diseases of the eye
Petit, L., Khanna, H., & Punzo, C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.040 · Cited by 82
“The first study was carried out by subretinal delivery of recombinant adeno-associated virus (AAV) 2 vectors expressing the wild-type canine Rpe65 cDNA under the control of the ubiquitous chicken b-actin (CBA) promoter.(7) This study revealed a dramatic improvement in photoreceptor function and vision in treated dogs.”
Two decades of clinical gene therapy--success is finally mounting.
Herzog, R. W., Cao, O., & Srivastava, A. (2010) · PubMed · Cited by 102
Gauthier, R., Joly, S., Pernet, V., Lachapelle, P., & Di Polo, A. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0362 · Cited by 80
“Most gene therapy strategies tested in animal models of retinal degeneration have relied on direct delivery of therapeutic genes to the affected cell type, such as photoreceptors or retinal pigment epithelium.(8,47,48) In the current study, we explored a novel, alternative approach based on delivery of the BDNF gene t…”
Duisit, G., Conrath, H., Saleun, S., Folliot, S., Provost, N., Cosset, F.-L., Sandrin, V., Moullier, P., & Rolling, F. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0690 · Cited by 79
Bioengineering strategies for restoring vision
Cehajic-Kapetanovic, J., Singh, M. S., Zrenner, E., & MacLaren, R. E. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00836-4 · Cited by 79
Pawlyk, B. S., Bulgakov, O. V., Liu, X., Xu, X., Adamian, M., Sun, X., Khani, S. C., Berson, E. L., Sandberg, M. A., & Li, T. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.218 · Cited by 79
“Proof-of-principle experiments in animal models have been conducted for several forms of LCA, with various degrees of success (Flannery et al., 1997; Acland et al., 2001; Narfstrom et al., 2003; Dejneka et al., 2004; Pawlyk et al., 2005; Pang et al., 2006; Tan et al., 2009; Sun et al., 2010).”
Naturally occurring animal models with outer retina phenotypes
Baehr, W., & Frederick, J. M. (2009) · Vision Research · doi:10.1016/j.visres.2009.04.008 · Cited by 79
Schlichtenbrede, F. C., da Cruz, L., Stephens, C., Smith, A. J., Georgiadis, A., Thrasher, A. J., Bainbridge, J. W. B., Seeliger, M. W., & Ali, R. R. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.401 · Cited by 80
“A number of recent studies have clearly demonstrated either retardation of photoreceptor cell loss or functional improvement in animal models of retinal degeneration following AAV-mediated gene transfer [4,5,11,12,16].”
BackgroundResultPawlyk, B. S., Bulgakov, O. V., Sun, X., Adamian, M., Shu, X., Smith, A. J., Berson, E. L., Ali, R. R., Khani, S., Wright, A. F., et al. (2016) · Gene Therapy · doi:10.1038/gt.2015.93 · Cited by 77
Gehlbach, P. L., Demetriades, A. M., Yamamoto, S., Deering, T. G., Duh, E. J., Yang, H. S., Cingolani, C., Lai, H. C., Wei, L. L., & Campochiaro, P. A. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301931 · Cited by 84
Retinal Nerve Fiber Layer Defects in RP Patients
Walia, S., Fishman, G. A., Edward, D. P., & Lindeman, M. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0404 · Cited by 77
Gekeler, F., Szurman, P., Grisanti, S., Weiler, U., Claus, R., Greiner, T.-O., Völker, M., Köhler, K., Zrenner, E., & Bartz‐Schmidt, K. U. (2006) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-006-0339-x · Cited by 75
“Other options, including retinal stem cell transplantation [19, 20, 28], gene therapy [2, 6] and neurotransmitter-based devices [18], are still further away from clinical application.”
BackgroundA Single, Abbreviated RPGR-ORF15 Variant Reconstitutes RPGR Function In Vivo
Hong, D.-H., Pawlyk, B. S., Adamian, M., Sandberg, M. A., & Li, T. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-1065 · Cited by 75
Treatment of Diabetes and Long-Term Survival After Insulin and Glucokinase Gene Therapy
Callejas, D., Mann, C. J., Ayuso, E., Lage, R., Grifoll, I., Roca, C., Andaluz, A., Fernández, R. R. D. G. I., Montané, J., MUÑOZ, S. A., et al. (2013) · Diabetes · doi:10.2337/db12-1113 · Cited by 99
“In the most clear-cut examples of success, clinical studies of hemophilia B (12) and Leber congenital amaurosis (11) were preceded by convincing studies of efficacy in large animal models (13,14).”
BackgroundAdvances in gene therapy technologies to treat retinitis pigmentosa
Petrs-Silva, H., & Linden, R. (2013) · Clinical Ophthalmology · doi:10.2147/opth.s38041 · Cited by 74
Wu, M., Chen, Y., Zhang, L., Li, X., Cai, X., Du, Y., Zhang, L., & Shi, J. (2014) · Journal of Materials Chemistry B · doi:10.1039/c4tb01581a · Cited by 75
Gene therapy in the second eye of RPE65-deficient dogs improves retinal function
Annear, M. J., Bartoe, J. T., Barker, S. E., Smith, A. J., Curran, P. G., Bainbridge, J. W., Ali, R. R., & Petersen-Jones, S. M. (2011) · Gene Therapy · doi:10.1038/gt.2010.111 · Cited by 74
Weleber, R. G., Michaelides, M., Trzupek, K. M., Stover, N. B., & Stone, E. M. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6106 · Cited by 74
Recent developments in ocular gene therapy
Borrás, T. (2003) · Experimental Eye Research · doi:10.1016/s0014-4835(03)00030-7 · Cited by 74
Mihelec, M., Pearson, R. A., Robbie, S. J., Buch, P. K., Azam, S. A., Bainbridge, J. W. B., Smith, A. J., & Ali, R. R. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.069 · Cited by 72
“Gene supplementation studies have been performed in a number of animal models of retinal degeneration, with increasingly encouraging results (Ali et al., 2000; Acland et al., 2001; Pawlyk et al., 2005; Alexander et al., 2007; Tan et al., 2009; Komaromy et al., 2010; Simons et al., 2011).”
BackgroundNaturally Occurring Cancers in Dogs: Insights for Translational Genetics and Medicine
Alvarez, C. E. (2014) · ILAR Journal · doi:10.1093/ilar/ilu010 · Cited by 73
“Both those models have shown significant clinical improvement, with gene therapy addressing the pathological mutations ofDystrophin and RPE65, respectively (Acland et al. 2001; Bainbridge et al. 2008).”
BackgroundImproved Hepatic Gene Transfer by Using an Adeno-Associated Virus Serotype 5 Vector
Mingozzi, F., Schüttrumpf, J., Arruda, V. R., Liu, Y., Liu, Y.-L., High, K. A., Xiao, W., & Herzog, R. W. (2002) · Journal of Virology · doi:10.1128/jvi.76.20.10497-10502.2002 · Cited by 73
Metadata
- Authors
- Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., Jacobson, S. G., Hauswirth, W. W., & Bennett, J.
- Affiliations
- Cornell University (US)
- University of Pennsylvania (US)
- University of Florida (US)
- Corresponding author
- Bennett, Jean
- ORCID
- Venue
- Nature Genetics
- Published
- 2001-05
- Volume
- 28
- Issue
- 1
- Pages
- 92-95
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2141354154
- Cited by
- 1,202
- References
- 21
- Citations by year
- 2026: 29 · 2025: 26 · 2024: 19 · 2023: 24 · 2022: 26 · 2021: 38 · 2020: 35 · 2019: 36 · 2018: 39 · 2017: 41 · 2016: 33 · 2015: 40 · 2014: 56 · 2013: 48 · 2012: 64
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ey011142-05)
- National Eye Institute (EY10820, EY 06855, R01EY010820, EY 11142, R01EY013132, R01EY011123, EY-11123, EY 13132)
- National Institute of Neurological Disorders and Stroke (NS36202)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- gene therapy, Leber congenital amaurosis, RPE65, retinal pigment epithelium, photoreceptors, recombinant adeno-associated virus, childhood blindness, vision restoration, inherited retinal degeneration, large animal model
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Animals, Blindness, Carrier Proteins, Disease Models, Animal, Dog Diseases, Dogs, Eye Proteins, Proteins, Genetic Therapy, Optic Atrophies, Hereditary, cis-trans-Isomerases, Animals, Genetically Modified
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.